PEDIATRIC ONCOLOGY GROUP--THE CAROLINAS CONSORTIUM

儿科肿瘤学集团--卡罗莱纳州联盟

• 批准号: 2009114
• 负责人: JOSEPH LAVER
• 金额: $ 15.62万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-06-15 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2009114
• 关键词: 6 thiopurine; Ewing's tumor; Hodgkin's disease; Wilms' tumor; XomaZyme; acivicin; acute leukemia; acute lymphocytic leukemia; acute myelogenous leukemia; adolescence (12-20); antineoplastics; asparaginase; astrocytoma; biological response modifiers; bone marrow transplantation; brain neoplasms; cancer registry /resource; cancer risk; central nervous system neoplasms; child (0-11); chronic myelogenous leukemia; cis platinum compound; clinical research; clinical trial phase I; colony stimulating factor; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; cyclosporines; cytosine arabinoside; daunorubicin; deferoxamine; deoxycoformycin; doxorubicin; drug screening /evaluation; enalapril; ependymoma; etoposide; fazarabine; fluorouracil; germ cell neoplasms; glioma; hepatoblastoma; hepatocellular carcinoma; human genetic material tag; human immunodeficiency virus 1; human subject; human therapy evaluation; human tissue; ifosfamide; interferons; interleukin 2; medulloblastoma; melphalan; metastasis; methotrexate; minimal residual disease; mitoxantrone; molecular oncology; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neuroblastoma; nonHodgkin's lymphoma; osteosarcoma; paclitaxel; pediatric pharmacology; podophyllin; prednisone; retinoate; rhabdomyosarcoma; tetrahydrofolylpolyglutamate synthase; tissue resource /registry; topotecan; trimetrexate; vincristine

DESCRIPTION (Adapted from the applicant's description): The institutions included in this proposal have been part of the Pediatric Oncology Group (POG) and received good performance scores during the past five years. There are two primary goals of this proposed research; the first is to accrue patients to the Group clinical trials in order to determine the optimal care of children with all types of cancers. The second is to contribute scientific expertise to the Group in areas of both patient care and tumor biology. This proposed research will allow participation in POG activities through a consortium effort of East Carolina University (ECU) School of Medicine, Carolinas Medical Center, Medical University of South Carolina (MUSC), Greenville Hospital, Presbyterian Hospital, and Memorial Mission Hospital (The Carolinas' Consortium). In addition to these clinical activities, their scientific efforts in next five years will include: (1) development of new protocols for the treatment of children with cancer focusing mainly on pediatric lymphomas; (2) expansion of studies of minimal marrow residual disease (using RT-PCR analysis) and assessment of new purging techniques in neuroblastoma; (3) participation in the laboratory evaluation of folylpolyglutamate synthetase (FPGS) in lymphoblasts of newly diagnosed patients; and (4) evaluation of the role hematopoietic growth factors in the treatment of pediatric malignancies.

描述（根据申请人的描述改编）：机构 包括在这个提案中的是儿科肿瘤学小组的一部分， (POG)并在过去五年中取得良好成绩。 这项研究的主要目标有两个：第一， 招募患者参加本集团临床试验，以确定 为患有各种癌症的儿童提供最佳护理。 二是 为集团在病人护理和医疗保健领域提供科学专业知识， 和肿瘤生物学 这项拟议的研究将允许参与POG 通过东卡罗莱纳大学（ECU）的联合努力开展的活动 南方医科大学医学院，南卡罗来纳医学中心 卡罗莱纳（MUSC）、格林维尔医院、长老会医院和纪念医院 使命医院（The Mission ' Consortium）。 除了这些临床 在未来五年内，他们的科学工作将包括：（1） 制定治疗儿童癌症的新方案 主要集中在小儿淋巴瘤;（2）扩大研究的最小 骨髓残留病（使用RT-PCR分析）和评估新的 神经母细胞瘤的净化技术;（3）参与实验室 新生儿淋巴母细胞中叶酸聚谷氨酸合成酶（FPGS）的评价 诊断患者;和（4）造血生长的作用评价 治疗小儿恶性肿瘤的因素。